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GENERAL INTRODUCTION/BACKGROUND [MG] 
 
Anaemia is a common finding in patients presenting for major elective surgery and is 
associated with a range of poor outcomes including death, postoperative complications 
and increased duration of hospitalisation.1 Iron deficiency is the leading cause of 
anaemia and may be due to nutritional factors, impaired absorption or chronic blood 
loss associated with underlying disease.2, 3 
 
The causal relationship between anaemia and poor outcomes remains unclear and 
anaemia may simply reflect other comorbidities or severity of underlying disease. 
Despite the association between anaemia and poor outcomes, guidance supports 
restrictive transfusion practice. Blood transfusion may be associated with increase risk 
of infection, tumour recurrence, fluid overload or transfusion reactions. Patient blood 
management (PBM) approaches focus on the early detection and treatment of 
preoperative anaemia with the aim of reducing the requirement for blood transfusion, 
improving patient outcomes.4 
 
Intravenous iron is considered to be an effective and safe treatment for iron deficiency 
anaemia and is recommended by expert opinion for treatment of preoperative anemia 
in patients where oral iron is not tolerated, is ineffective or where there is insufficient 
time for treatment with oral iron prior to surgery.5 Intravenous iron has widespread 
recommendation in PBM guidelines although there is minimal high quality evidence to 
support this. The PREVENTT trial was a large multicentre trial investigating the effects 
of in intravenous iron on red cell transfusion, death, complications and quality of life 




The use of intravenous iron in patients with anaemia before major open elective 
abdominal surgery increased haemoglobin concentrations before surgery but did not 
reduce the frequency of blood transfusion or mortality in the perioperative period 





The principal finding of this multi-centre randomised placebo controlled trial was that 
there was no difference in the co-primary outcomes of blood transfusion or death, or 
the number of transfusion episodes, within 30 days after surgery, in patients that 
received preoperative intravenous iron therapy compared to placebo.6 The incidence of 
blood transfusion or death was 67/237 (28.3%) in the intravenous iron group and 69/237 
(29.1%) in the placebo group.  The mean (SD) number of transfusion episodes was 0.47 
(0.9) in the intravenous  iron group compared to 0.44 (0.9) in the placebo group. There 
were no differences in the secondary or safety outcomes between treatment groups and 
there was no effect in any of the pre-specified sub-group analyses. The results of this 




The original and independent discussions agree on the the principal findings of this 
trial: administration of intravenous iron therapy did not reduce a composite outcome of 
transfusion or death when compared with placebo. Although intravenous iron therapy 
appears to be safe, this trial does not support its routine use in the treatment of 
preoperative anaemia in major abdominal surgery. 
 
Relationship of main finding to previous studies 
Original discussion 
PREVENTT reduces the uncertainty created by two previous small trials on the use of 
preoperative intravenous iron. The IVICA trial from Nottingham, U.K., looked at 116 
patients with anaemia undergoing colorectal cancer surgery and found that intravenous 
iron had no effect on blood transfusion use, whereas a smaller trial of 72 patients in 
Australia, found that intravenous iron for patients with iron deficiency anaemia (ferritin 
<300 mcg/L, transferrin saturation <25%) did reduce perioperative blood transfusion 
(12% vs. 31%).20 PREVENTT suggests that preoperative intravenous iron has no 




The relationship between preoperative anaemia and increased risk of postoperative 
morbidity and mortality is well described.1 However, there is limited evidence to 
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support clinical strategies to increase haemoglobin concentration and consequently 
improve perioperative clinical outcomes. Among cardiac surgical patients, a meta-
analysis of 8886 patients found that a liberal  red cell transfusion strategy did not reduce 
mortality or morbidity (pulmonary, cardiac, infective, renal or cerebrovascular 
complications) compared to a restrictive strategy.7 However, in non-cardiac surgery 
patients a meta-analysis of 7552 patients from 17 randomised trials suggested that a 
liberal transfusion strategy was associated with lower mortality compared to a 
restrictive strategy.8 Among patients undergoing hip fracture repair a liberal transfusion 
strategy was associated with increased risk of stroke, while a restrictive strategy was 
associated with higher risk of acute coronary syndrome.9 Since patients with 
preoperative anaemia are more likely to receive perioperative red cell transfusion, it 
seems intuitive that increasing the preoperative haemoglobin concentration would 
reduce the incidence of blood transfusion.1 In a meta-analysis of eight studies (two 
randomised trials and six observational studies) including 812 patients undergoing non-
cardiac surgery the rate of transfusion was lower among patients that received 
intravenous iron.10 However, this was evident only among observational studies and 
the randomised trials, suggesting the positive result may be influence by bias.11, 12 A 
similar story is seen in cardiac surgery, where meta-analysis of pooled data from four 
randomised trials suggest that preoperative intravenous iron therapy does not reduced 
the incidence of mortality, hospital length of stay or renal injury, but there was a 
reduction in the rate of blood transfusion. The results of the PRVENTT trial support 
evidence from previous small trials that preoperative intravenous iron therapy does not 
reduce perioperative red cell transfusion among patients undergoing non-cardiac 
surgery.11-13 This calls into question the increasingly common practice of preoperative 
iron infusion for patients with anaemia, which has crept into perioperative practice with 
only very limited supporting evidence. Patient blood management strategies to reduce 
the need for allogenic red cell transfusion are very important, but clinicians should 




Perioperative anaemia is common and the practice of intravenous iron admininstration 
prior to elective surgery has been adopted widely despite limted evidence to support its 
use. Both the original discussion and independent discussion agree that until the 
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PREVENTT trial, intravenous iron has only been investigated in small randomised 
trials with conflicting results. Red cell transfusion is the most commonly studied 
clinical outcome in trials of intravenous iron, but the optimal red cell transfusion 
strategy is not defined in the surgical population particularly if there is coexisting 
cardiac disease. Systematic reviews of clicinal trials suggest that in non-cardiac 
surgery, restrictive startegies may be associated with increased risk of death or 
myocardial infarction. While more research is required to resolve the controversy 
surrounding perioperative red cell transfusion threshold, the findings from PREVENTT 
suggest not only that intravenous iron admisinstration does not influence the 
requirement for red cell transfusion, but that like liberal red cell transfusion another 
strategy aimed at increasing haemoglobin in the perioperative period has not translated 
to clinical benefit for patients. 
 
Additional (secondary) findings and relationship to other studies 
Original discussion 
There was no reduction in the risk of postoperative in-hospital complications or length 
of hospital stay, and no benefits to quality of life. However, there was a reduced risk of 




In the PREVENTT trial, patients who received intravenous iron therapy had higher 
mean haemoglobin concentrations compared to placebo, an effect which lasted for at 
least six months.15 This supports previous trials that have demonstrated the efficacy of 
intravenous iron therapy to treat iron deficiency anaemia. The outcomes of patients with 
intravenous iron were not significantly different to patients treated with placebo in 
almost all domains. Patients treated with intravenous iron were less likely to be 
readmitted to hospital within 8 weeks after their surgical procedures. However, this did 
no persist up to 6 months after surgery and may represent a chance finding. Importantly, 
the incidence of serious adverse events and serious unexpected adverse reactions were 
similar in each treatment group, with only 4.6% of patients experiencing some form of 






The independent discussion highlights that in  the PREVENTT trial participants treated 
with intravenous iron had higher hemoglobin concentrations at 6 months and that the 
incidence of adverse reactions were similar between groups. This would suggest that 
intravenous iron is a safe and effective treatment for iron deficiency anaemia. 
Intravenous iron did not however reduce postoperative complications, duration of 
hospitalisation or quality of life. Those treated with intravenous iron were significantly 
less likely to be readmitted to hospital within the first 8 weeks following surgery. The 
reasons for this are unclear and appears due to what the authours define as surgical 
complications. It is possible this could represent a chance finding, as it is difficult to 
link anaemia and surgical complications with a biologically plausible hypothesis. Aside 





The trial has several strengths, including allocation concealment, double-blinding, 
placebo control, high levels of adherence to the trial intervention (481/487), and low 
levels of attrition, with 474 of 487 participants providing data for the primary intention-
to-treat analyses. There was no difference between the results of the per-protocol and 
intention-to-treat analyses or between the predefined subgroups, suggesting that 
nonadherence with other components of the protocol was unlikely to have influenced 
the trial result. The study included patients with a range of anaemia profiles including 
mild anaemia. These strengths, along with the broad inclusion criteria, clear 
documentation of process, and absence of effectiveness across a range of primary and 
secondary outcomes, support the validity and generalisability of the trial results. 
 
Independent discussion 
This multi-centre randomised placebo-controlled trial has several strengths. First, the 
use of a placebo addresses limitations of previous trials, which have often compared 
intravenous iron to either oral iron supplementation or standard clinical care, risking 
the introduction of bias. Second, the multi-centre design makes the results of this trial 
widely generalizable to the majority of patients undergoing major non-cardiac surgery. 
Third, the co-primary outcomes of allogenic red cell transfusion or death, and number 
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of units of red cells transfused are clinically relevant outcomes. That there is no 
difference in these outcomes between the treatment groups is an important, potentially 
practice changing result.  
 
Commentary [MG] 
Optimal use of intravenous iron is an important clinical question regarding an 
intervention in widespread use with low quality evidence to support it. A large, 
pragmatic, mulicentre, placebo controlled trial with clinically relevant endpoints was 
required and PREVENTT has the validity needed to answer this question. The vast 
majority of the patients enroled in the trial received the study intervention. The broad 
inclusion criteria mirrored the population likely to receive and is widely generalisable 
to clinical practice. The study results will change clinical practice in anaemic patients 
undergoing non-cardiac surgery, and allow resources to be prioritised in to other more 




One limitation was that preoperative iron deficiency was not defined as an inclusion 
criterion although a predefined subgroup analysis was performed for those patients with 
a Ferritin < 100ng/ml and Transferrin Saturations < 20% in line with current guidelines 
for preoperative iron deficiency14, of whom 57% had a Ferritin <100 ng/ml and 76% 
had transferrin saturations <20%  at inclusion and randomisation to the trial. There was 
no evidence of interaction between treatment in these predefined subgroups for the co-
primary endpoints of the study.  
 
Independent discussion 
This trial also has limitations. First, patient recruitment (n=487) did not meet the target 
sample size (n=500) and the rate of blood transfusion (29.1%) is less than the expected 
40% used in the sample size calculation. While it is possible that the trial is statistically 
underpowered, this is unlikely to make a difference in the interpretation of the primary 
analysis. Second, due to the complex pathway for patients undergoing surgery, the care 
of one in five participants deviated from the trial protocol. While this is not unexpected 
for trials of complex intervention among surgical patients, it is possible that this may 
have introduced bias and reduced the magnitude of any differences between groups. 
8 
 
Third, due to the requirement for a preoperative clinic visit for the iron infusion, patients 
requiring urgent surgery may not have been enrolled in the trial due to concerns about 
actual or perceived delays in care. Therefore, it is possible that the sample may not 
represent patients with very severe surgical disease that may have benefited the most 




The independent discussion identifies several noteable limitations not highlighted in 
the original discussion. Most importantly the study is likely to be underpowered as it 
did not meet the predefined sample size and the incidence of red cell transfusion was 
considerably less than the estimate used to power the study. Bias may also have arisen 
from a large number of protocol deviations and lack of predefined red cell transfuison 
criteria, which was the primary endpoint.  Finally concerns about delays in definitive 
treatment for more urgent patients, who would require additional clinic visits to receive 
the intervention with the potential to delay definitive treatment, may have excluded 
patients with more severe disease. 
 
Directions for future research 
Original discussion 
Our findings have several important clinical implications. The treatment effect on mean 
haemoglobin values was higher after surgery than in the preoperative setting, despite 
no differences in type of surgery, bleeding, or transfusion volumes between the groups. 
The effect of preoperative intravenous iron and increased post-operative haemoglobin 
levels associated with reduced readmission to hospital for surgical complications merits 
further investigation. This may reflect an underlying mechanism of functional or 
absolute iron deficiency and anaemia of chronic disease with inflammation, and 
subsequent stimulus of blood loss at operation.  Clinically, this raises the possibility 
that postoperative intravenous iron, before discharge from the hospital, may be 
effective at boosting haemoglobin levels in surgical patients during their recovery 
period. Post-operative intravenous iron would be easier and less expensive than 
intravenous iron preoperatively because the patient would already be in the hospital, 
being nursed and monitored in a hospital bed, and likely have venous access in situ. 
This approach is unlikely, however, to be any more effective than preoperative 
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intravenous iron in accruing benefits to the primary outcomes measured in our trial.  
Our findings are consistent with the existing evidence on iron therapy in non-cardiac 
patients. Trials of interventions to reverse anaemia, either with iron therapy or more 
liberal transfusion thresholds, have failed to demonstrate important clinical 
benefits,22,23 despite observational evidence that anaemia is associated with poorer 
outcomes. This implies that treatments directed to  the underlying causes of anaemia 
may be required to improve outcomes in this high-risk population.  
 
Independent discussion 
There is a clear and persistent increase in haemoglobin concentration in patients that 
received intravenous iron. However, the clinical significance of this finding is uncertain 
and could be explored to determine whether there is a long-term health benefit in excess 
of the follow-up period of the PREVENTT trial. While there was no effect of 
preoperative intravenous iron therapy on perioperative allogenic blood transfusion or 
mortality, there was a reduction in hospital readmission within eight weeks after 
surgery. The explanation for this is unclear and it may represent a chance finding, but 
this should be explored further. There is a clear relationship between preoperative 
anaemia and poor clinical outcomes after surgery. However, management strategies 
targeted at increasing haemoglobin levels, including perioperative blood transfusion, 
have shown variable and sometimes conflicting results. The optimum threshold of 
haemoglobin concentration to trigger perioperative blood transfusion after non-cardiac 
surgery is uncertain and needs further study.  
 
Commentary [MG] 
There is a clear association between anaemia and poor outcomes after surgery. 
Intravenous iron is an effective treatment for iron deficiency anaemia and in this study 
its use lead to a sustained improvements in haemoglobin concentration. Whether 
intravenous iron use is associated with other long term benefits is unknown. The 
optimum use of perioperative red cell transfusion is also unknown and requires further 
investigation. Whether particulaur surgical groups e.g. cardiac surgery, orthopaedic 
surgery or elderly surgical patients may benefit from intravenous iron is the subject of 







In conclusion, PREVENTT showed that intravenous iron was not superior to placebo 
when administered to patients with anaemia 10 to 42 days before elective major 




Intravenous iron infusion was not associated with a reduction perioperative allogenic 
red cell transfusion or death within 30 days after surgery. These results do not support 
the routine use of preoperative intravenous iron infusion. 
 
Commentary [MG] 
The  PREVENTT trial suggests that intravenous iron is a safe effective treatment for 
perioperative anaemia however its use in anaemic patients having major abdominal 
surgery did not reduce the incidence of red cell transfusion, death or an range of other 
outcomes including complications hospitalisation or quality of life. Routine use of 
intravenous iron in patients having noncardiac surgery cannot be recommended and 
should be reconsidered until further evidence is available. 
 
Inferential reproducibility [MG &TEFA] 
The major inferential differences relate to some of the limitations of the PREVENTT 
trial and its position within the contextual landscape of patient blood management. 
Although PREVENTT represents the best evidence available to guide perioperative use 
of intravenous iron, it is likely that the study was underpowered and this is not 
acknowledged prominently in the original discussion. There was no standardisation or 
advice on transfusion strategy in trial patients although this was the primary endpoint 
and considerable controversy and variation in practice is known to exist in this regard. 
However, we acknowledge that in the context of already widespread adoption of 
preoperative intravenous iron therapy, this trial was likely very difficult to conduct 
since many clinicians may have felt they lacked equipoise.  More research is required 
to define the optimum red cell transfusion strategy for patients undergoing surgery. 
Finally the original discussion does not consider that there may be other surgical groups 
(e.g. the elderly, cardiac surgery) who may benefit from this intervention. Nonetheless 
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in most aspects the independent and original discussion are in agreement, particularly 
in the interpretation of the study findings and their implications. This is an important 
study which should change clinical practice and reminds us of the pitfalls of 
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